摘要
目的分析尿肌氨酸在前列腺癌(CAP)诊断和病情判断方面是否优于血清前列腺特异性抗原,甚至优于后者。方法以同位素稀释液相色谱质谱法检测CAP及良性前列腺增生症(BPH)患者和健康者尿肌氨酸水平,电化学发光法检测血清PSA水平,荧光原位杂交(FISH)技术检测前列腺组织ERG基因异位和TMPRSS2/ERG融合基因。结果 CAP组、BPH组和健康对照组尿肌氨酸水平分别为(6.930±5.619)、(2.250±2.237)和(2.058±1.396)μmol/L,CAP组高于健康对照组和BPH组(P<0.05)。84.6%(11/13)的CAP患者具有ERG基因异位或TMPRSS2/ERG融合基因。2例疑为CAP的BPH组患者尿肌氨酸水平升高,且检出TMPRSS2/ERG融合基因。结论尿肌氨酸有可能成为可用于诊断CAP的具有一定临床应用价值的肿瘤标记物。
Objective To analyze whether urinary sarcosine could be as good as,or even better than serum prostate specific antigen（PSA） in the diagnosis and prognosis of carcinoma of prostate（CAP）.Methods Isotope dilution-liquid chromatography mass spectrometry（LC/MS） was performed for the detection of urinary sarcosine level of patient with CAP or benign prostatic hyperplasia（BPH） and healthy controls.Electrochemiluminescence assay was used for the detection of serum PSA level.Fluorescence in situ hybridization（FISH） was used for the detection of translocation gene ERG and TMPRSS2/ERG fusion gene in prostate tissues.Results The urinary sarcosine levels of CAP,BPH and healthy control group were（6.930±5.619）,（2.250±2.237） and（2.058±1.396） μmol/L,and that of CAP group was higher than the other groups（P〈0.05）.11 cases of CAP group were positive with translocation gene ERG or TMPRSS2/ERG fusion gene.2 cases of BHP group,with a suspect diagnosis of CAP,were with high levels of urinary sarcosine and positive with TMPRSS2/ERG fusion gene.Conclusion Urinary sarcosine could be used as a useful tumor marker for the diagnosis of CAP
出处
《国际检验医学杂志》
CAS
2011年第12期1299-1300,共2页
International Journal of Laboratory Medicine
关键词
前列腺肿瘤
肌氨酸
质谱分析法
Prostatic neoplasms
sarcosine
mass spectrometry
